Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis

• Published in: Antimicrobial agents and chemotherapy Vol. 63; no. 10
• Main Authors: Li, Hanbin, Salinger, David H, Everitt, Daniel, Li, Mengchun, Del Parigi, Angelo, Mendel, Carl, Nedelman, Jerry R
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.10.2019
• Subjects: Antitubercular Agents; Clinical Therapeutics; Diarylquinolines; Linezolid; Long QT Syndrome; Models, Statistical; Nitroimidazoles; Tuberculosis, Multidrug-Resistant; multidrug resistance; Mycobacterium tuberculosis; antimicrobial agents; tuberculosis
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/AAC.00445-19

Concentration-QTc modeling was applied to pretomanid, a new nitroimidazooxazine antituberculosis drug. Data came from eight phase 2 and phase 3 studies. Besides pretomanid alone, various combinations with bedaquiline, linezolid, moxifloxacin, and pyrazinamide were considered; special attention was given to the bedaquiline-pretomanid-linezolid (BPaL) regimen that has demonstrated efficacy in the Nix-TB study in subjects with extensively drug-resistant or treatment-intolerant or nonresponsive multidrug-resistant tuberculosis. Three heart rate corrections to QT were considered: Fridericia's QTcF, Bazett's QTcB, and a population-specific correction, QTcN. QTc increased with the plasma concentrations of pretomanid, bedaquiline's M2 metabolite, and moxifloxacin in a manner described by a linear model in which the three slope coefficients were constant across studies, visits within study, and times postdose within visit but where the intercept varied across those dimensions. The intercepts tended to increase on treatment to a plateau after several weeks, a pattern termed the secular trend. The slope terms were similar for the three QTc corrections, but the secular trends differed, suggesting that at least some of the secular trend was due to the elevated heart rates of tuberculosis patients decreasing to normal levels on treatment. For pretomanid 200 mg once a day (QD) alone, a typical steady-state maximum concentration of drug in plasma ( ) resulted in a mean change from baseline of QTcN of 9.1 ms, with an upper 90% confidence interval (CI) limit of 10.2 ms. For the BPaL regimen, due to the additional impact of the bedaquiline M2 metabolite, the corresponding values were 13.6 ms and 15.0 ms. The contribution to these values from the secular trend was 4.0 ms.